Inferra AIResearch Tools

Inferra AI / Company / EXEL

Exelixis, Inc.

EXEL · Health Care

Last earnings Oct 29, 2026

Key results

Total revenuequarter

$597.8 million

com Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $597.8 million, Cabozantinib Franchise U.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

U.S Net Product revenuequarter

$542.9 million

Franchise U.S. Net Product Revenues of $542.9 million - -

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Net Product revenuequarter

$542.9 million

Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5 00 PM Eastern Time - ALAMEDA, Calif.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

GAAP EPSquarter

$0.69

Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5 00 PM Eastern Time - ALAMEDA, Calif.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Non-GAAP EPSquarter

$0.78

Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5 00 PM Eastern Time - ALAMEDA, Calif.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Revenuequarter

$542.9 million

Total revenues for the quarter ended September 30, 2025 included net product revenues of $542.9 million, as compared to $478.1 million for the comparable period in 2024.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

were $542.9 million during the third quarter of 2025, with net product revenues of $539.9 million from CABOMETYX (cabozantinib) and $3.1 million from COMETRIQ (cabozantinib).

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Based upon cabozantinib-related net product revenues generated by Exelixis collaboration partners during the quarter ended September 30, 2025, Exelixis earned $46.3 million in royalty revenues.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

AI analysis

Q3 2025 · reported Nov 4, 2025

Based on: Earnings release + parent 8-K — transcript not held

Total revenue · Q3 2025
$597.8M
+25.0% +$120M vs year ago computed from stated figures
EX-99 · Nov 4, 2025
GAAP EPS · Q3 2025
$0.69
EX-99 · Nov 4, 2025
Non-GAAP EPS · Q3 2025
$0.78
EX-99 · Nov 4, 2025
U.S Net Product revenue · Q3 2025
$542.9M
+4.4% vs prior quarter computed from stated figures
EX-99 · Nov 4, 2025

The quarter in charts

Revenue — quarterly

As stated

0250500750$478.1MSame quarter last year$597.8MQ3 2025

EX-99 · Nov 4, 2025 Statement values as stated in the release.

Segment mix

Business-unit revenue, as stated

0200400600$542.9MU.S Net Product$542.9MNet Product

Segment revenue figures as stated in the event record.

Headline figures

MetricQ3 2025Prior qtrYear ago
Total revenue$597.8 million$568.3 million$478.1 million
U.S Net Product revenue$542.9 million$520.0 million—
Net Product revenue$542.9 million$520.0 million—
GAAP EPS$0.69$0.65—
Non-GAAP EPS$0.78$0.75—
Revenue$542.9 million$568.3 million$478.1 million

EX-99 · Nov 4, 2025

Guidance · company-stated

Direction: Initiated

Company outlook — Initiated

“federal government shutdown Exelixis plans to initiate additional zanzalintinib pivotal trials, including in the post-chemotherapy adjuvant CRC settings, as well as in high grade and or recurrent meningiomas, and plans for its early-stage pipeline the timing of completion for Exelixis corporate reorganization plan by the end of fiscal year 2025 Exelixis updated financial guidance for fiscal year 2025 and any plans to provide further updates the timing, amount, and completion of any stock repurchase programs and Exelixis scientific pursuit to create transformational treatments that give more patients hope for the future.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Net Product revenue$542.9M
GAAP EPS$0.69
Non-GAAP EPS$0.78

Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5 00 PM Eastern Time - ALAMEDA, Calif.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Based on these results, we intend to complete the submission of our first new drug application for zanzalintinib in the U.S

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Initiated

Company outlook — Initiated (“initiate”)
“federal government shutdown Exelixis plans to initiate additional zanzalintinib pivotal trials, including in the post-chemotherapy adjuvant CRC settings, as well as in high grade and or recurrent meningiomas, and plans for its early-stage pipeline the timing of completion for Exelixis corporate reorganization plan by the end of fiscal year 2025 Exelixis updated financial guidance for fiscal year 2025 and any plans to provide further updates the timing, amount, and completion of any stock repurchase programs and Exelixis scientific pursuit to create transformational treatments that give more patients hope for the future.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5 00 PM Eastern Time - ALAMEDA, Calif.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

GAAP net income per share for the quarter ended September 30, 2025 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended September 30, 2025, as compared to the comparable period in 2024, as a result of the stock repurchase programs.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Stock Repurchase Program.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

In August 2024, Exelixis Board of Directors authorized a stock repurchase program (SRP) to acquire up to $500 million of the company s common stock before December 31, 2025.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

In February 2025, the Board of Directors authorized the repurchase of up to an additional $500 million of the company s common stock before December 31, 2025.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Under these programs, as of September 30, 2025, Exelixis has repurchased $895.3 million of the company s common stock, at an average price of $37.18 per share.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Strategy & priorities

In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategic priorities across the research development portfolio, said Michael M.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

A trend for improvement in progression-free survival (PFS) with the combination was also observed in the ITT population, though statistical superiority cannot be claimed at this time due to the prespecified hierarchical testing strategy.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Risks & headwinds

Forward-looking statements involve risks and uncertainties.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

What changed vs prior quarter

Guidance direction — prior quarter: Reiterated; this quarter: Initiated

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Total revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

U.S Net Product revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Exelixis, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

34 documents

Earnings releases

10 documents

Presentations

0 documents

No presentations for Exelixis, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Exelixis, Inc. are held in this edition of the library.

Mentioned by

2 companies

Other tracked companies whose held documents mention Exelixis, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.